Streetbeat News

Products Services

AAL

Graphyte, a company specializing in carbon removal, has signed its first purchase agreement with American Airlines for the removal of 10,000 tons of carbon dioxide. This deal marks a significant step for Graphyte in the carbon offset market and demonstrates American Airlines' commitment to reducing its carbon footprint.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:11 pm

CRWD

HPE

INTU

NTAP

PDD

QQQ

SPLK

SPY

WDAY

Stock futures indicate a cautious sentiment as traders await consumer confidence and house price data, along with Fed speeches. The energy sector may benefit from oil's rebound ahead of the OPEC+ meeting. The S&P 500 is trading above analysts' 12-month consensus forecast, which is seen as a bullish signal. Retail stocks are in focus due to Cyber Monday sales, while several companies including Zscaler, PDD Holdings, CrowdStrike, Hewlett Packard Enterprise, Intuit, Splunk, NetApp, and Workday are set to report earnings. Crude oil futures are up, and Bitcoin has risen above $37,000.

Portfolio Pulse from Shanthi Rexaline

November 28, 2023 | 12:06 pm

CARM

Carisma Therapeutics has received FDA clearance for its Investigational New Drug (IND) application for CT-0525, a novel HER2-targeting CAR-monocyte therapy. The company plans to begin a Phase 1 study soon and anticipates treating the first patient in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:05 pm

NTRB

Nutriband Inc. has expanded its product line with the launch of AI Tape Heating and Cooling, which are additions to its AI Kinesiology Tape portfolio. These new products aim to provide users with the benefits of both heating and cooling therapy in conjunction with kinesiology taping techniques.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:05 pm

ALTR

Altair has announced the launch of its RapidMiner 2023 platform, which introduces advanced generative AI capabilities. The new features include auto-clustering, enhanced coding capabilities for SAS, Python, and R, among other updates.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:04 pm

GXO

GXO Logistics has extended its agreement with Amer Sports, including added returns services. This extension solidifies GXO's position as a key logistics provider for Amer Sports, potentially increasing GXO's revenue and customer base.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 12:03 pm

BABA

Alibaba Group Holding Limited (NYSE:BABA) stock is trading lower after reports of a second outage in its cloud unit within a month. The disruption affected customers in China, Hong Kong, and the U.S., impacting various database management products. The company, which holds a significant market share in China's cloud market, also faced a similar issue in November. Concerns over the reliability of Alibaba Cloud's services have been raised. Additionally, Alibaba halted plans to spin off its cloud business and closed its quantum computing lab, signaling cost-cutting efforts. BABA shares are down 16.1% YTD and dropped 1.0% in premarket trading.

Portfolio Pulse from Anusuya Lahiri

November 28, 2023 | 12:00 pm

TELUS released its 5th annual Indigenous Reconciliation & Connectivity Report, highlighting progress on reconciliation commitments and a new goal to integrate Indigenous perspectives into its AI strategy. The report includes artwork by Indigenous artists and stories of Indigenous Peoples leveraging TELUS' connectivity for community benefits.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 11:48 am

DIS

MSFT

OpenAI, backed by Microsoft Corp. (NASDAQ:MSFT), has announced the ability to create custom GPTs. A user has utilized this feature to develop a custom GPT bot that can transform photos into Pixar characters, owned by Walt Disney Co. (NYSE:DIS). The bot, named Storybook Vision, uses Dall-E 3 for the transformation and requires a ChatGPT Plus subscription for use, as the free version does not support custom GPTs.

Portfolio Pulse from Rounak Jain

November 28, 2023 | 11:44 am

SWTX

The FDA has approved SpringWorks Therapeutics Inc's Ogsiveo for adult patients with progressing desmoid tumors, marking it as the first drug for this condition. The approval is based on the Phase 3 DeFi trial results, which showed a 71% reduction in the risk of disease progression and a 41% objective response rate compared to placebo. Ogsiveo will be available in the U.S. soon and a European application is expected in the first half of 2024. Analysts project U.S. sales of $3 million in 2023, $79 million in 2024, and peak sales of $544 million in 2032. SpringWorks' shares rose 9.24% in premarket trading.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 11:43 am